Michael Offin

7.6k total citations · 1 hit paper
97 papers, 2.1k citations indexed

About

Michael Offin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Michael Offin has authored 97 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pulmonary and Respiratory Medicine, 42 papers in Oncology and 21 papers in Cancer Research. Recurrent topics in Michael Offin's work include Lung Cancer Treatments and Mutations (50 papers), Cancer Genomics and Diagnostics (21 papers) and Occupational and environmental lung diseases (19 papers). Michael Offin is often cited by papers focused on Lung Cancer Treatments and Mutations (50 papers), Cancer Genomics and Diagnostics (21 papers) and Occupational and environmental lung diseases (19 papers). Michael Offin collaborates with scholars based in United States, Italy and Canada. Michael Offin's co-authors include Charles M. Rudin, Mark G. Kris, Alexander Drilon, Marc Ladanyi, Maria E. Arcila, Bob T. Li, Matthew D. Hellmann, Gregory J. Riely, Helena A. Yu and Hira Rizvi and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael Offin

87 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

2019 289 citations Ryma Benayed, Michael Offin et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Offin United States	23	1.5k	1.1k	550	492	240	97	2.1k
Anas Gazzah France	22	861 0.6×	1.3k 1.2×	553 1.0×	355 0.7×	259 1.1×	99	2.1k
Carol Peña France	7	875 0.6×	765 0.7×	910 1.7×	492 1.0×	217 0.9×	9	2.3k
Wei‐Xiang Qi China	24	940 0.6×	1.1k 1.0×	426 0.8×	227 0.5×	391 1.6×	109	2.1k
Lorenza Landi Italy	22	1.0k 0.7×	1.1k 1.0×	611 1.1×	423 0.9×	107 0.4×	85	1.8k
Éric Dansin France	19	1.8k 1.2×	1.4k 1.3×	376 0.7×	330 0.7×	127 0.5×	113	2.4k
Isabelle Rouquette France	28	1.8k 1.2×	1.6k 1.4×	675 1.2×	671 1.4×	317 1.3×	85	2.8k
Miloš Pešek Czechia	21	1.7k 1.2×	1.6k 1.5×	650 1.2×	408 0.8×	133 0.6×	110	2.4k
Purvish Parikh India	9	2.1k 1.5×	1.8k 1.6×	521 0.9×	412 0.8×	186 0.8×	21	2.6k
Jindřich Fínek Czechia	23	607 0.4×	874 0.8×	368 0.7×	402 0.8×	176 0.7×	161	1.5k
Pavlos Papakostas Greece	26	841 0.6×	1.5k 1.4×	439 0.8×	315 0.6×	448 1.9×	104	2.2k

Countries citing papers authored by Michael Offin

Since Specialization

Citations

This map shows the geographic impact of Michael Offin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Offin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Offin more than expected).

Fields of papers citing papers by Michael Offin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Offin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Offin. The network helps show where Michael Offin may publish in the future.

Co-authorship network of co-authors of Michael Offin

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Offin. A scholar is included among the top collaborators of Michael Offin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Offin. Michael Offin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Soo‐Ryum, Kay See Tan, Prasad S. Adusumilli, et al.. (2025). Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma. Modern Pathology. 38(5). 100706–100706. 2 indexed citations

Ahn, M-J., Ibiayi Dagogo‐Jack, Francesco Gelsomino, et al.. (2024). LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). Annals of Oncology. 35. S1246–S1247. 2 indexed citations

Offin, Michael, Daphna Y. Gelblum, Fernando C. Santini, et al.. (2024). Exploratory analysis of CTDNA and imaging response in Phase I/II chorus study of canakinumab with chemoradiation and durvalumab for NSCLC. 5. 100232–100232. 1 indexed citations

Offin, Michael, Michelle S. Ginsberg, Prasad S. Adusumilli, et al.. (2024). Combining a WT1 cancer vaccine (galinpepimut-S) with checkpoint inhibition (nivolumab) in patients with WT1-expressing diffuse pleural mesothelioma (DPM): A phase I study.. Journal of Clinical Oncology. 42(16_suppl). 8083–8083. 1 indexed citations

Choudhury, Noura J., W. Victoria Lai, Alex Makhnin, et al.. (2024). A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer. Clinical Cancer Research. 30(17). 3697–3703. 14 indexed citations

Yang, Soo‐Ryum, Jamal Benhamida, Jason C. Chang, et al.. (2024). Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features. Clinical Cancer Research. 30(13). 2780–2789.

Yu, Helena A., Monica F. Chen, Angela Bik‐Yu Hui, et al.. (2024). A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease.. Journal of Clinical Oncology. 42(16_suppl). 8517–8517. 6 indexed citations

Elkrief, Arielle, Igor Odintsov, Roger S. Smith, et al.. (2024). Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification. JCO Precision Oncology. 8(8). e2400241–e2400241. 3 indexed citations

Imber, Brandon S., Rupesh Kotecha, Rosemary J. Young, et al.. (2024). Multi-Center Phase I Study of Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases (BM) or Leptomeningeal Metastases (LM) Harboring PI3K Pathway Mutations. International Journal of Radiation Oncology*Biology*Physics. 120(2). S193–S193.

10.

Federico, Alessandro Di, Monica F. Chen, A. Pagliaro, et al.. (2024). 1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer. Annals of Oncology. 35. S826–S827.

11.

Marmarelis, Melina E., Xiao Wang, Leonid Roshkovan, et al.. (2023). Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma. JAMA Network Open. 6(3). e232526–e232526. 7 indexed citations

12.

Li, Yan, Marina K. Baine, Francis M. Bodd, et al.. (2023). Reliability of assessing morphologic features with prognostic significance in cytology specimens of epithelioid diffuse pleural mesothelioma and implications for cytopathology reporting. Cancer Cytopathology. 131(8). 495–506. 3 indexed citations

13.

Yang, Soo‐Ryum, Jason C. Chang, Charles Leduc, et al.. (2021). Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling. Journal of Thoracic Oncology. 16(7). 1188–1199. 20 indexed citations

14.

Offin, Michael, Soo‐Ryum Yang, Jacklynn V. Egger, et al.. (2021). Molecular Characterization of Peritoneal Mesotheliomas. Journal of Thoracic Oncology. 17(3). 455–460. 35 indexed citations

15.

Shepherd, Annemarie F., Jonathan E. Leeman, Brandon S. Imber, et al.. (2020). Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy. Practical Radiation Oncology. 11(1). e52–e62. 12 indexed citations

16.

Benayed, Ryma, Michael Offin, Kerry Mullaney, et al.. (2019). High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clinical Cancer Research. 25(15). 4712–4722. 289 indexed citations breakdown →

17.

Offin, Michael, Hira Rizvi, Megan Tenet, et al.. (2018). Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers. Clinical Cancer Research. 25(3). 1063–1069. 230 indexed citations

18.

Suzawa, Ken, Michael Offin, Daniel Lu, et al.. (2018). Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer. Clinical Cancer Research. 25(4). 1248–1260. 83 indexed citations

19.

D, Liu, et al.. (2018). Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. SHILAP Revista de lepidopterología. 4 indexed citations

20.

Xiao, Wenbin, Mariko Yabe, Michael Offin, et al.. (2018). Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation. Blood Advances. 2(13). 1517–1521. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact